God, AIDS, Africa & HOPE

Reflections / Gedanken

POZ Magazine: Forecasting the Future of HIV

As much as $722 billion might be needed to tackle HIV by 2031, if no cure or vaccine is found, according to new research published in The Lancet and reported by PlusNews. Study authors predict that in the next 20 years, annual HIV infections will be halved to about 1.2 million. However, new treatment guidelines will raise costs by 43 percent, and about one third of funding must be spent in Africa to stop the epidemic.  Researchers noted that the amount of money needed could drop to $400 billion if countries restructured their AIDS funding policies now.

To read the PlusNews story, click here.

Source: http://www.poz.com/rssredir/articles/Future_OF_HIV_1_19243.shtml

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Medical and Research, Politics and Society, , , , , ,

14.10.2010 Days flying…

This week, time is flying because days are somehow booked out and between morning and evening lies one meeting after the other. I sometimes wonder how much one can take on different faces, different approaches, different worries, different joys until one mixes all up and is oneself mixed up – somehow..

But there is also success: the new HOPE Cape Town feature is done and on the way to Dresden – at the HOPE Gala in Dresden the feature will meet for the first time an interested audience.  HOPE Cape Town management meeting is gone and many issues solved, discussed, put onto the right track. The re-structuring of the organization to be more professional in its efforts to combine grass root and research is on the right path to realisation. My trip to Europe becomes more and more a detailed one with lots of interesting meetings and presentations, and in between two galas, one in Dresden (HOPE Gala Dresden) and one in Berlin (AIDS Gala Berlin). I will meet old friends and hopefully new future supporters of HOPE Cape Town. The expectations are always high and time will tell whether I am able to match my own ones..  🙂

And a big birthday celebration is in waiting: Brother Joachim – Joachim Franz – is turning 50 years in November and I am looking forward to a great evening full of laughter and joy. And at the same time some serious discussion for the World AIDS Awareness Campaign 2011 – beginning in April next year. A real challenge, watch the space. This block will report on every detail of this indeed challenging campaign.

This week saw also discussions about the future of CAN, the Catholic AIDS Network of the Archdiocese of Cape Town as well as the  future of POZ, the initiative of pastoral care for priests and religious living with the virus… Nothing is easy, nothing is set in stone, all developing and obviously at the end should stand nothing more than a meaningful service for fellow men.

Filed under: HIV and AIDS, HOPE Cape Town Association & Trust, Society and living environment, , , , , , , , ,

POZ Magazine: Therapeutic Vaccine Achieves “Functional Cure” in Monkeys

Therapeutic Vaccine Achieves “Functional Cure” in Monkeys

The monkey version of a therapeutic vaccine by VIRxSYS Corporation achieved a “functional cure”—fully controlling simian immunodeficiency virus (SIV) production and halting disease progression in a subset of vaccinated monkeys.
VIRxSYS has been pursuing gene therapy against HIV for several years, but it has been exploring a therapeutic vaccine as well. Its technology involves packaging HIV’s genetic material within a molecular delivery vehicle, commonly known as a vector. The company is using a lentivirus as the vector for its current vaccine, dubbed VRX1273.
As a step before human testing, VIRxSYS scientists gave a simian version of its VRX1273 vaccine or a placebo to several monkeys in their laboratory. After the monkeys were vaccinated, they were infected with a virulent strain of SIV. Gary McGarrity, PhD, executive vice president of scientific and clinical affairs at VIRxSYS, in Gaithersberg, Maryland, reported the results of this experiment at the AIDS Vaccine 2010 conference, which was held September 28 to October 1 in Atlanta.
Two of the five monkeys that received VRX1273 were able to maintain full control of SIV. In the placebo group, several of the monkeys died, providing evidence that VRX1273 both controls SIV reproduction in infected monkeys and provides a survival benefit.
“We and HIV key opinion leaders are very optimistic about these long-term results showing viral suppression, protection of the immune system and survival in this prophylactic study,” McGarrity said. “In addition, the full control of SIV replication following infection of two of our monkeys is a significant milestone in our research to develop effective therapeutic and prophylactic vaccines for HIV.”

Source:  http://www.poz.com/articles/hiv_virxsys_vaccine_761_19211.shtml

Filed under: HIV and AIDS, HIV Treatment, Medical and Research, Uncategorized, , ,

POZ Magazine: New Computer Modeling System Predicts Which HIV Combos Are Best

Researchers in London announced October 6 the launch of a free-of-charge, online computer modeling system to help providers choose the antiretroviral (ARV) combinations that will most likely work for their patients.

For people starting their first ARV regimen, the choices are usually pretty clear. Given that all of the combinations recommended by the Department of Health and Human Services HIV treatment guidelines panel have proved effective at controlling HIV, the choice usually comes down to which combination will be easiest to take and have the least troubling side effects.

For people who are on their third, forth or fifth regimens, however—or those who are infected with drug-resistant HIV—treatment decisions can be challenging. Currently, providers must sort through the often complex results of genotype tests, which identify the drug-resistant mutations a person’s HIV carries, along with a person’s treatment history to determine what combinations are most likely to work. In the most complex cases, providers often consult with resistance experts at university academic centers.

Now, a group of researchers belonging to a non-profit group called the Response Database Initiative has launched a new online computer modeling program to help providers make more accurate predictions about the best regimens for their patients. Called the HIV Treatment Response Prediction System (HIV-TRePS), the system uses computer simulations based on the medical records of over 70,000 people with HIV around the world to determine which treatments will be best for a specific individual.

To use the system, a provider enters a person’s genotypic test results, viral load, CD4 count and treatment history. Within seconds, the system returns to the provider a list of potential combinations, sorted by their potency and tolerability.

“This is a very exciting development—the system literally puts the experience of treating thousands of different patients at the doctor’s fingertips,” commented Julio Montaner, MD, from the BC Centre for Excellence in HIV & AIDS in Vancouver. “This has the potential to improve outcomes for people living with HIV and AIDS around the world, particularly where resources and expertise are scarce.”

HIV-TRePS is only about 78 percent accurate in its predictions, and its developers caution that it should not be substituted for expert medical guidance. It has, nevertheless, proven more effective than other available methods, which have about 54 percent accuracy, for predicting which regimens will be most likely to work.

“We are really excited about the launch of this system, which is a milestone for us, our research partners around the world and also for the use of bioinformatics in medicine,” said Brendan Larder, PhD, scientific chair of RDI. “We believe this approach can make a significant difference in a variety of settings and diseases.”

Source: http://www.poz.com/rssredir/articles/hiv_resistance_treps_761_19217.shtml

Filed under: HIV and AIDS, HIV Treatment, Medical and Research, , , ,

POZ Magazine: Considering Cannabis – e.g. USA

In states where it is legal, medical marijuana helps some HIV-positive people cope with living their lives.

In the states of California and Washington, since 1996 and 1998, respectively, medical marijuana has been legally available for people with HIV, cancer and other serious health challenges. Heading west this past spring from my home in Connecticut, I set out to learn about the states’ medi-pot programs. Okay, I admit it. I also hoped to score a bit of medicine, too.
Nationally, 14 states plus the District of Columbia allow medical marijuana use. Most of these consider anyone with HIV/AIDS eligible for medical pot. Many HIV-positive people use marijuana to treat nausea, appetite loss, the pain of neuropathy, chronic bowel problems and even anxiety. “When appropriately prescribed and monitored,” the American Academy of HIV Medicine stated in 2007, “marijuana/cannabis can provide immeasurable benefits for the health and well-being of our patients.”

So it is not surprising that some people with HIV use marijuana for medical purposes, whether it’s legal or not. And a whopping 89 percent of the men participating in the long-term Multicenter AIDS Cohort Study (MACS) acknowledged using pot, though they weren’t asked whether it was legally obtained.  In Seattle, I interviewed Robert Wood, MD, recently retired AIDS chief for the Seattle/King County public health department. Based on his experience, which dates to the early 1980s, Wood said pot helps many positive people in the aforementioned ways. And while it seems to help some people sleep, he noted, it can have the opposite effect for others.  John Moore, a San Francisco man living with HIV since 2004, told me his doctor recommended pot to treat lipoatrophy. “Weed does not help lipoatrophy [a condition that results in loss of body fat], OK?” he said, fairly winking. But it can alleviate the emotional impact of lipo and other HIV side effects. “It provides a sense of well-being and allows me to get away temporarily from anxieties,” Moore said. “Some would say it’s an illusion, but so what? I think we should be looking at it like any other medicinal substance.”

Indeed, the placebo effect can be useful. As Josiah Rich, MD, professor of medicine and community health at Brown Medical School at Providence, Rhode Island, said: “Whether the benefit is from marijuana or from the belief that it is helping, it has a real effect for some people suffering from symptoms related to HIV or HIV meds.”  The road to legalization has been long. In 1999, the Institute of Medicine, which advises the federal government on scientific matters, asserted “the potential therapeutic value for cannabinoid drugs.” But it took until last year for the American Medical Association to sign on. Moreover, federal law still outlaws marijuana. But in 2009, the justice department directed prosecutors to lay off people using medical cannabis in states where it’s legal. In San Francisco, the city instructed the police department not to arrest people for having medical marijuana. Apparently, the directive worked. “I get on the bus in the morning,” Moore said, “and the whole thing reeks of weed because so many people are carrying it.”
Unfortunately for me, California, like all the other medical pot states, limits the use of legal marijuana to state residents. Only a few states offer reciprocity for visitors from other legal-marijuana states who run out of medicine.
Obtaining medical pot is a pretty standard process for residents of the states offering it. First, you need a doctor’s medical recommendation (not a prescription). If having HIV isn’t enough, your doctor will want to know what specific ailments you are trying to address.
The referral—and a fee, ranging from $100 in Michigan to $150 in Nevada—will get you a one-year, state-issued ID card, usually from the state health department. Some states have dedicated medical pot offices, such as Vermont’s Marijuana Registry. The ID card allows you to avoid arrest and—important for people with compromised immune systems—avoid low-quality marijuana, possibly mixed with mystery compounds. You might pick up your new medicine in a state-licensed dispensary or “compassion center,” as Rhode Island calls them. In most states, a license also entitles you to grow a limited amount of pot. (See sidebar for further details.) Moore described the San Francisco dispensary he uses as a trailer-type building—like a teashop, but with bulletproof glass. “Behind [that] glass,” he explains, “is a woman sitting with a cash register. A white board on the wall lists what they have. Then there are big jars with different types [of cannabis]”—bearing names such as Purple Haze and White Widow. “Everything is priced by an eighth of an ounce,” Moore said. Prices are as high as $60 for high-quality grass, to a mere $20 for what’s commonly called “shake,” the stems and seeds that can be added to melted butter to make a spread. Insurance companies and third-party payers won’t (yet?) pay for medical marijuana, so it’s all out of pocket.

I didn’t see the dispensary, but Moore did take me into a smoke shop on 18th Street, half a block from the intersection of Castro, and pointed out the shelf of vaporizers. Instead of smoking, he uses one of these. “You put the weed in this little mesh chamber at the end of a short hose,” he said. “And you attach that above a heating element that heats but does not burn the herb, then inhale from the other end.“  Smoking pot can harm the lungs, the Institute of Medicine first warned in 1999. In contrast, vaporizers produce “little or no exposure” to the unhealthy chemicals smoking generates, including carbon monoxide and benzene, according to University of California at San Francisco researchers, led by longtime HIV and cancer doctor Donald Abrams, MD. What’s more, they found that a vaporizer produced higher plasma levels of THC (tetrahydrocannabinol, marijuana’s 
active ingredient) than smoking. Back in Providence, in his HIV clinic, Josiah Rich recommends a vaporizer to avoid lung damage. “But,” he adds, “smoking small amounts is not unreasonable.” In the name of research, I tried a vaporizer. As promised, the device eliminates the coughing and irritation associated with smoking weed. Beyond the known risks of smoking, there’s been at least a squeak of a warning about cannabis for people with HIV—from a “humanized” mouse. Researchers at UCLA infected a specially engineered mouse with an HIV-like virus, then gave it THC. They concluded the cellular damage they observed could mean that THC might slightly speed up the progress of untreated HIV. But Abrams found that neither smoked nor synthetic THC—dronabinol, in prescription Marinol tablets—affects viral load or interacts with HIV meds. In fact, he said, the research shows that marijuana “actually improved immune function after 21 days of smoking three times a day.” And so far, no other research has confirmed those mousy data. All medications have side effects and trade-offs. For example, the side effects of the HIV meds I take are diarrhea, headache, nausea, stomach pain or upset, tiredness, vomiting and weakness. By contrast, marijuana, whose most common side effect is “euphoric mood,” stacks up amazingly well.
Source: http://www.poz.com/articles/Medical_Marijuana_HIV_2521_18907.shtml

Filed under: HIV and AIDS, HIV Treatment, Medical and Research, Politics and Society, , , , , ,

Blog Categories

Follow God, AIDS, Africa & HOPE on WordPress.com

You can share this blog in many ways..

Bookmark and Share

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,711 other subscribers

Translation – Deutsch? Française? Espanol? …

The translation button is located on each single blog page, Copy the text, click the button and paste it for instant translation:
Website Translation Widget

or for the translation of the front page:

* Click for Translation

Copyright

© Rev Fr Stefan Hippler and HIV, AIDS and HOPE.
Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Rev Fr Stefan Hippler and HIV, AIDS and HOPE with appropriate and specific direction to the original content.

This not withstanding the following applies:
Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 3.0 Unported License.